Pharmacokinetics of inhaled levosimendan: a pilot study
Levosimendan is a medicine that helps the heart pump blood more easily and relaxes blood vessels. At present, patients usually receive it through a drip directly into a vein in hospital. This pilot study is testing a new approach: breathing the medicine into the lungs through an inhaler or nebuliser. Researchers want to measure how the drug moves through the body when it is inhaled. They will track how much medicine enters the bloodstream, how long it stays there, and how the body breaks it down. Because this is an early Phase 1 trial, the main focus is on safety and understanding how the body handles this new method. Finding simpler ways to deliver heart medications could make treatments easier and more comfortable for patients in the future. The trial is open to adults aged 18 and over.
At a glance
What is this study about?
Heart failure happens when the heart muscle becomes too weak or stiff to pump blood around the body as effectively as it should. This can leave people feeling tired, breathless, and prone to fluid build-up in their legs or lungs. Doctors use various medicines to support the heart. One of these is levosimendan, a drug that helps the heart muscle contract more strongly while opening up blood vessels to improve blood flow.
Currently, levosimendan is given through a vein using a drip, which usually means a stay in hospital. In this trial, scientists are testing whether patients can take levosimendan by inhaling it as a fine mist instead. Breathing the medicine straight into the lungs could be a gentler, needle-free option that works quickly and might reduce the need for hospital drips.
This trial is a pilot study, meaning it is an early, small-scale test. Researchers want to study the 'pharmacokinetics' of the inhaled drug—a scientific term for how a medicine travels into, through, and out of the human body. The team will carefully measure the amount of drug that reaches the blood and check for any unwanted reactions.
Learning how the inhaled version behaves is a crucial first step. If this pilot study shows that the medicine is safe and well absorbed, doctors can then plan larger trials to see how well it relieves heart failure symptoms in everyday life.
Key takeaways
- Tests an inhaled mist form of the heart failure medicine levosimendan.
- Aims to discover how the body absorbs, processes, and removes the inhaled drug.
- Open to adults aged 18 and over with heart failure.
- Involves breathing in the medicine and having regular blood tests and heart checks.
- Participation is voluntary, and you can leave the study at any time.
Who may be eligible?
This study is open to men and women aged 18 and older who have heart failure. Because this is an early safety and absorption trial, the research team needs to ensure it is completely safe for each person who joins.
To take part, you will need a confirmed diagnosis of heart failure, and your current health will need to be stable enough for the tests. The researchers will look closely at your medical history, kidney function, and the medications you currently take to make sure none of them interfere with the study drug.
You may not be able to join if you have very low blood pressure, severe kidney or liver problems, or certain lung conditions that could make inhaling a mist difficult. Women who are pregnant or breastfeeding will also not be able to take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with heart failure by a doctor.
- I am able to use an inhaler or breathe through a nebuliser mask.
- My current health and heart condition are reasonably stable.
- I am not pregnant or breastfeeding.
What does participation involve?
Taking part usually involves visiting a specialist hospital clinic for one or more sessions. Before anything begins, the team will run health checks, including blood tests, an electrocardiogram (ECG) to monitor your heart rhythm, and blood pressure checks. If you are eligible, you will breathe in a carefully measured dose of levosimendan mist through a mouthpiece or mask. After you take the medicine, staff will take regular, small blood samples over several hours to measure how much of the drug has entered your bloodstream. You will be closely monitored by doctors and nurses throughout your stay. The team will also arrange follow-up contact, either by phone or at a clinic visit, to check how you are feeling. The entire study typically lasts from a few days to a few weeks, depending on the schedule of visits.
Potential risks and benefits
Locations (1)
- —UnverifiedBelgium
Common questions
What is levosimendan?
Levosimendan is a prescription heart medicine that helps the heart muscle pump more effectively and opens up blood vessels to reduce strain on the heart.
Why test an inhaled version?
Currently, levosimendan is given through a drip into a vein. Inhaling it through the lungs could be quicker, avoid needles, and allow the medicine to work directly where it is needed.
Will taking part cure my heart failure?
No. This trial is designed to see how the body absorbs the inhaled drug, not to cure the condition. It may not provide any direct personal health benefit.
Do I have to pay to take part?
No, clinical trials run through hospitals do not charge participants. The study medication and all trial tests are provided free of charge, and travel expenses are often covered.
Can I leave the trial if I feel uncomfortable?
Yes. You can leave the study at any point without giving a reason. Your standard medical care will continue as normal.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.